www.fdanews.com/articles/208245-innodem-neurosciences-etna-designated-an-fda-breakthrough-device-for-ms
Innodem Neurosciences’ ETNA Designated an FDA Breakthrough Device for MS
June 16, 2022
Innodem Neurosciences’ ETNA mobile eye tracking technology for multiple sclerosis (MS) patients has been designated a Breakthrough Device by the FDA.
The software app records eye movements to help estimate the severity and track the progression of the disease. It is intended for individuals with a diagnosis of MS who have oculomotor symptoms.
The app runs off-the-shelf electronic tablets, turning them into devices that capture eye movements. It can then remotely inform clinicians about MS disease progression so they can adjust treatment and improve patient outcomes.